Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Efficacy of Cervarix in Brazilian Women
NCT00518336Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2007
- Primary completion
- Jul 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (2 arms), sponsored by GSK. Primary endpoint: Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18. Started Nov 2007; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00518336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00518336.